Clozapine monitoring requirements: is it time for an update?
| Autor: | Fernandez-Egea E; Cambridgeshire and Peterborough NHS Foundation Trust and Department of Psychiatry, University of Cambridge, Cambridge, UK., McCutcheon RA; Department of Psychiatry, University of Oxford, Oxford, Oxford Health NHS Foundation Trust, Oxford and Department of Psychosis Studies, Institute of Psychiatry, Psychology and Neuroscience, King's College, London, UK. |
|---|---|
| Jazyk: | angličtina |
| Zdroj: | The British journal of psychiatry : the journal of mental science [Br J Psychiatry] 2024 Oct 03, pp. 1-3. Date of Electronic Publication: 2024 Oct 03. |
| DOI: | 10.1192/bjp.2024.150 |
| Abstrakt: | Oloyede and colleagues advocate for updating haematological monitoring requirements for clozapine, arguing that current protocols overestimate the risk of clozapine-induced agranulocytosis. Their research suggests that stringent monitoring may unnecessarily limit access to clozapine, a crucial treatment for resistant schizophrenia. The editorial supports calls for international consensus to carefully weigh the pros and cons of relaxing monitoring guidelines while ensuring comprehensive care for patients. |
| Databáze: | MEDLINE |
| Externí odkaz: |
|